- July 2019
- October 2019
- December 2019
- September 2020
Company founded by Dr. Lieping Chen (Yale University) to pioneer the next generation of immunotherapies to treat cancer and autoimmune disease and to collaborate with academic and industry partners, addressing significant unmet medical needs and providing patients worldwide with access to new innovations.
Completed our first licensing deal with immuno-oncology pioneers Drs. Lieping Chen (Yale University) and Yuwen Zhu (University of Colorado, Denver), obtaining world-wide rights to CD93, a novel therapeutic target resulting from pioneering research into malignant tumor vasculature, aiming to turn the tumor microenvironment (TME) from immunosuppressive to immunostimulatory and to enhance the efficacy of immunotherapies and chemotherapeutic agents.
Licensed second target (undisclosed) based on the research of Dr. Lieping Chen to advance our mission and focus on autoimmune disease.
Moved into 17,000 square foot laboratory and office space at current headquarters at 830 Winter Street in Waltham, Massachusetts.
DynamiCure Doses First Patients in Phase 1 Clinical Trial of Lead Antibody Candidate DCBY02 in Advanced CancersNovember 8, 2022
The lead candidate from DynamiCure’s anti-CD93 program, DCBY02 targets a wide range of metastatic solid tumors Phase 1 trial aims to assess the safety and anti-tumor activity of the candidate in dose-escalation and dose-expansion phases of the study Waltham, MA — November 8, 2022 — DynamiCure, a private biopharmaceutical company…
DynamiCure Announces IND Clearance to Advance First Antibody Candidate from its DC-6001 Anti-CD93 Program into Clinical DevelopmentAugust 22, 2022
DCBY02 to be assessed in patients with advanced or metastatic solid tumors across dose-escalation and dose-expansion parts of a Phase 1 clinical study Waltham, MA — August 22, 2022 — DynamiCure, a private biopharmaceutical company translating pioneering immuno-normalization insights into a pipeline of innovative therapeutic antibody candidates, today announced that…